CD4 and breast cancer: In breast TME, TILs are predominantly activated T lymphocytes (CD3+/CD56−, CD4+, or CD8+-T cells) [10], with their increase associated with good prognosis in TNBC patients [24–26] and chemotherapy response in BC patients [24, 27–29].